Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Open-label Phase 3 Study to Compare IBI354 With or Without Pertuzumab vs. Taxane in Combination With Trastuzumab and Pertuzumab as First-line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Breast Cancer

NCT07377643 is registered in ClinicalTrials.gov with Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. as lead sponsor.

NCT NCT07377643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07377643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Open-label Phase 3 Study to Compare IBI354 With or Without Pertuzumab vs. Taxane in Combination With Trastuzumab and Pertuzumab as First-line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Breast Cancer
Lead sponsor
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase
Phase 3
Overall status
Recruiting
Start date
February 10, 2026
Completion date
May 31, 2030
Enrollment
540 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer